Back to News
Market Impact: 0.3
Fate Therapeutics Receives $15M CIRM Grant To Advance FT819 In Lupus Nephritis
Source: Nasdaq
Healthcare & BiotechGreen & Sustainable Finance
Fate Therapeutics received a $15.0 million CLIN2 grant from the California Institute for Regenerative Medicine to support clinical development of its iPSC-derived cellular immunotherapies. The non-dilutive funding is a positive catalyst for the clinical-stage biotech, although the article excerpt does not specify the program, development milestone, or financial impact beyond the grant amount.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
FATE0.55
More News
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Details on U.S.-China trade negotiations coming Monday, USTR Greer says
- At Meta Connect, the company’s smart glasses were everywhere
- ShinyHunters tells The Reg: We hacked the FBI to 'protect our business'
- For months, OpenAI’s agent swarms have been attacking online databases to find obscure facts
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate Consensus Estimates Platforms With AI
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More